As a leader in haemostasis management, Novo Nordisk recognises that there is a significant need for improving haemophilia treatment and infrastructure in developing countries. In 2005 the company therefore set up the Novo Nordisk Hemophilia Foundation (NNHF) as a commitment to the company’s social responsibility for haemophilia care.
In developing countries, haemophilia care is currently not a healthcare priority, and haemophilia and inhibitor patients go undiagnosed. Life expectancy for people with haemophilia is therefore short and treatment with clotting factors is suboptimal.
NNHF is dedicated to supporting the improvement of haemophilia care through the funding of sustainable local and regional projects. These projects involve stakeholders within the haemophilia community such as healthcare professionals, patient associations, governments and non-governmental organisations.
NNHF focuses on increasing awareness and diagnosis of haemophilia with or without inhibitors (antibodies against clotting factors) as well as on improving understanding of haemophilia, the organisation of its treatment and prevention of complications from the disease. NNHF operates on an annual donation of approximately 10 million Danish kroner from Novo Nordisk, granted for an indefinite period of time.
Performance 2005
To date, four projects in Algeria, Poland, Uzbekistan and Venezuela have received approval for NNHF funding from 2005 onwards, and many more projects from around the world are in the pipeline. NNHF also makes an annual award to an outstanding private or professional individual within the haemophilia community for their contribution to disease betterment.
This page has been assessed by PricewaterhouseCoopers as part of its assessment of Novo Nordisk’s statement that it reports ‘in accordance’ with GRI. Please refer to Audit and assurance for a full description of the nature of assurance offered.
